FindTrial
Sign In

In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patient to ceftolozane/tazobactam and ceftazidime/avibactam

In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patient to ceftolozane/tazobactam and ceftazidime/avibactam

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200222001
Enrollment
Unknown
Registered
2020-02-22
Start date
2020-03-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Susceptibility Burkholderia pseudomallei Thai patient Ceftolozane/tazobactam Ceftazidime/avibactam Ceftolozane/tazobactam Ceftazidime/avibactam Melioidosis Burkholderia pseudomallei

Interventions

Experimental Biological/Vaccine
ceftolozane/tazobactam and ceftazidime/avibactam susceptibility test
Susceptibility test of ceftolozane/tazobactam and ceftazidime/avibactam using E&#45
test strip on MHA and interpretation as CLSI criteria

Sponsors

Khon Kaen University
Lead Sponsor
Khon Kaen University
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Burkholderia pseudomallei which were isolated from blood, sputum, pus, or urine of the patients at Srinagarind hospital, Khon Kaen university from January 2020 until completion of study

Exclusion criteria

Exclusion criteria: no

Design outcomes

Primary

MeasureTime frame
Susceptibility of B. pseudomallei isolate to ceftolozane/tazobactam and ceftazidime/avibactam Janurary, 2020 until completion E-test and MIC—

Secondary

MeasureTime frame
No No No—

Countries

Thailand

Contacts

Public ContactWantin Sribenjalux
Wantinmd34@gmail.com+66858546585

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026